HeartSciences (HSCSW) Cash & Equivalents (2022 - 2026)

HeartSciences has reported Cash & Equivalents for 5 years, with the latest figure at $3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 30.83% year-over-year to $3.4 million; the trailing twelve-month figure through Jan 2026 stood at $3.4 million (up 30.83% YoY), and the FY2025 full-year result was $1.1 million, down 81.07% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $3.4 million, up from $2.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $7.1 million in Q1 2024, with the low at $100144.0 in Q4 2023.
• Historically, Cash & Equivalents has averaged $2.9 million across 5 years, with a median of $2.7 million in 2025.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 96.74% — and 2024, when it surged 3946.29%.
• HeartSciences' Cash & Equivalents stood at $3.1 million in 2022, then tumbled by 96.74% to $100144.0 in 2023, then surged by 3946.29% to $4.1 million in 2024, then plunged by 51.85% to $2.0 million in 2025, then surged by 74.11% to $3.4 million in 2026.
• The last three Cash & Equivalents figures came in at $3.4 million (Q1 2026), $2.0 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.